Alnylam commits $30 million upfront to AI startup Inceptive for RNA research collaboration

Alnylam Pharmaceuticals announced a new collaboration with Inceptive, a Silicon Valley biotech startup that focuses on RNA.

The agreement includes an upfront payment of $30 million and is intended to use artificial intelligence to accelerate Alnylam’s discovery research.

The partnership will combine Inceptive’s AI platform with Alnylam’s existing R&D pipeline to identify promising RNA targets more efficiently.

This is Alnylam’s first AI‑focused discovery deal, highlighting the growing interest in AI tools within the biotech industry.